ES3041133T3 - New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine - Google Patents

New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Info

Publication number
ES3041133T3
ES3041133T3 ES20704547T ES20704547T ES3041133T3 ES 3041133 T3 ES3041133 T3 ES 3041133T3 ES 20704547 T ES20704547 T ES 20704547T ES 20704547 T ES20704547 T ES 20704547T ES 3041133 T3 ES3041133 T3 ES 3041133T3
Authority
ES
Spain
Prior art keywords
dao
specifically
variant
recombinant
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20704547T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Böhm
Bernd Jilma
Nicole Borth
Elisabeth Gludovacz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical University of Vienna
University of Natural Resources and Life Sciences
Original Assignee
Medical University of Vienna
University of Natural Resources and Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical University of Vienna, University of Natural Resources and Life Sciences filed Critical Medical University of Vienna
Application granted granted Critical
Publication of ES3041133T3 publication Critical patent/ES3041133T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03022—Diamine oxidase (1.4.3.22)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/20—Sequence assembly
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Library & Information Science (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
ES20704547T 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine Active ES3041133T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157932 2019-02-19
PCT/EP2020/054197 WO2020169577A1 (en) 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Publications (1)

Publication Number Publication Date
ES3041133T3 true ES3041133T3 (en) 2025-11-07

Family

ID=65493995

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20704547T Active ES3041133T3 (en) 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Country Status (14)

Country Link
US (1) US20220145269A1 (enExample)
EP (1) EP3927817B1 (enExample)
JP (1) JP7792252B2 (enExample)
KR (1) KR20210132650A (enExample)
CN (1) CN113785052B (enExample)
AU (1) AU2020225319B2 (enExample)
BR (1) BR112021015865A2 (enExample)
CA (1) CA3130751A1 (enExample)
EA (1) EA202192305A1 (enExample)
ES (1) ES3041133T3 (enExample)
IL (1) IL285452B2 (enExample)
MX (1) MX2021010050A (enExample)
SG (1) SG11202107659SA (enExample)
WO (1) WO2020169577A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
WO2022072718A1 (en) 2020-09-30 2022-04-07 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
EP4496488A4 (en) * 2022-03-21 2025-11-26 Cedars Sinai Medical Center METHODS AND COMPOSITIONS FOR THE SUPPRESSION OF BIOGENIC AMINES PRODUCED BY THE INTESTINAL MICROBIOME
IL317379A (en) * 2022-06-03 2025-02-01 Oyster Point Pharma Inc AAV vector encoding diamine oxidase and its uses
EP4782002A1 (en) * 2025-01-27 2026-07-29 DR Healthcare S.L.U. Diamine oxidase (dao) for use in the treatment of infertility
CN121975758B (zh) * 2026-04-02 2026-07-14 华中科技大学同济医学院附属同济医院 组胺氧化酶蛋白及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK402785D0 (da) * 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
US6075007A (en) * 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
IT1317067B1 (it) * 2000-11-29 2003-05-26 Univ Roma Istaminasi di origine vegetale nel trattamento dello shock allergico esettico e nell'asma allergico.
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2536016C (en) * 2002-08-16 2017-01-10 Paul L. Deangelis Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
AT502098B8 (de) * 2004-07-07 2007-06-15 Albert Dr Missbichler Diaminooxidase-hältige zusammensetzung
CA2660286A1 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2012028891A1 (en) * 2010-09-02 2012-03-08 Debreceni Egyetem Perorally applicable preparation containing histaminase of vegetable origin, resistant to pepsin and trypsin and a process for producing it
JP2014518632A (ja) * 2011-06-01 2014-08-07 モアハウス スクール オブ メディスン ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法
AU2015332533B2 (en) * 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
WO2023122254A2 (en) * 2021-12-22 2023-06-29 The Board Of Trustees Of The Leland Stanford Junior University Methods to elicit desire to mate and mating behavior

Also Published As

Publication number Publication date
EP3927817C0 (en) 2025-08-20
AU2020225319B2 (en) 2025-05-29
KR20210132650A (ko) 2021-11-04
US20220145269A1 (en) 2022-05-12
BR112021015865A2 (pt) 2021-10-05
SG11202107659SA (en) 2021-09-29
WO2020169577A1 (en) 2020-08-27
CA3130751A1 (en) 2020-08-27
EP3927817B1 (en) 2025-08-20
CN113785052A (zh) 2021-12-10
IL285452B2 (en) 2025-07-01
CN113785052B (zh) 2024-06-28
IL285452A (en) 2021-09-30
MX2021010050A (es) 2021-09-21
JP2022520862A (ja) 2022-04-01
EP3927817A1 (en) 2021-12-29
AU2020225319A1 (en) 2021-10-14
IL285452B1 (en) 2025-03-01
JP7792252B2 (ja) 2025-12-25
EA202192305A1 (ru) 2021-12-08

Similar Documents

Publication Publication Date Title
EP3927817B1 (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
ES2883158T3 (es) Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
US11697678B2 (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
US9161966B2 (en) GDF15 mutein polypeptides
ES2910501T3 (es) Variantes y métodos de uso de Huwentoxin-IV
ES3037618T3 (en) Proteins with diagnostic and therapeutic uses
JP2018517726A (ja) 老化関連症状を治療するための方法および組成物
AU2020200352A1 (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US12104186B2 (en) Deimmunized lysostaphin and methods of use
EP4133067A1 (en) An enzyme
HK40064258A (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
HK40064258B (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
WO2014014819A2 (en) Methods of treating glucose metabolism disorders
TW201625678A (zh) 合成肽
NZ790135A (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
BR112017001789B1 (pt) Polipeptídeos, dímero, método de produção dos mesmos, composição farmacêutica, uso dos mesmos e recipiente estéril para tratamento de distúrbios metabólicos
WO2014014816A2 (en) Methods of treating glucose metabolism disorders